Back to Dashboard
NTLA · Healthcare

Intellia Therapeutics Inc

USA Healthcare Filing: 2026-06-30
29/100
Smart-money confidence1 of 3 sources positive
Below average interest

No standout activity across the feeds we track.

What this band has actually done: stocks scoring 25–45 beat the S&P 500 over the next three months 45.3% of the time, across 39,662 cases since 2015. That is below a coin flip — and so is every other band, because the median stock loses to a cap-weighted index. How we measured this

Hedge funds
39
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
Market cap
$1.6B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About INTELLIA THERAPEUTICS INC

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary…

Who's behind the signal
Every informed buyer we can see on NTLA, across all three feeds.
Hedge funds · 8
ARK Invest (Cathie Wood) Increased +16%
D.E. Shaw & Co Increased +12%
Point72 (Steve Cohen) Increased +48%
+2 more in the full breakdown below ↓
Congress · 3
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 12 on record
Disclosures from 2017-10-19 to 2022-02-28
The newest disclosure we hold for this stock is 2022-02-28. That is the end of our data, not necessarily the end of the trading — our bulk STOCK Act archive stops there and newer filings arrive through a separate live feed. Treat the absence of recent rows as “not covered”, not as “no trades”.
Trade date Member Chamber Action Amount
2022-02-28 Donald S. Beyer, Jr. · D-VA House Sold $15,001 - $50,000
2021-10-29 Donald S. Beyer, Jr. · D-VA House Sold $1,001 - $15,000
2021-09-20 Donald S. Beyer, Jr. · D-VA House Sold $1,001 - $15,000
2021-07-21 Donald S. Beyer, Jr. · D-VA House Sold $1,001 - $15,000
2021-01-15 Donald S. Beyer, Jr. · D-VA House Sold $1,001 - $15,000
2020-11-20 Thomas R. Carper · D-DE Senate Bought $1,001 - $15,000
2020-11-18 Donald S. Beyer, Jr. · D-VA House Bought $1,001 - $15,000
2020-08-26 Donald S. Beyer, Jr. · D-VA House Sold $1,001 - $15,000
2020-07-10 Donald S. Beyer, Jr. · D-VA House Bought $1,001 - $15,000
2020-01-14 Donald S. Beyer, Jr. · D-VA House Bought $1,001 - $15,000
Show the other 2
Trade date Member Chamber Action Amount
2018-10-25 James M. Inhofe · R-OK Senate Sold $15,001 - $50,000
2017-10-19 James M. Inhofe · R-OK Senate Bought $15,001 - $50,000
Not a model pick — but on our radar. INTELLIA THERAPEUTICS INC isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
8
Investors
1
New positions
5
Increasing
2
Decreasing
0
Unchanged
Price History
Loading price data...
A member of Congress bought A member sold
Return: High: Low:

Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.

Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Portfolio Allocation
How much of each investor's portfolio is allocated to INTELLIA THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell INTELLIA THERAPEUTICS INC or any security.

订阅每周更新

我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费,直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订